Predict your next investment

HEALTHCARE | Drug Discovery
cureveda.com

See what CB Insights has to offer

Stage

Seed | Alive

Total Raised

$100K

Last Raised

$100K | 6 yrs ago

About Cureveda

Cureveda is focused on the discovery, development and commercialization of novel small molecule drugs for the treatment of inflammatory, autoimmune and neurological diseases.

Cureveda Headquarter Location

1450 South Rolling Road

Halethorpe, Maryland, 21227,

United States

301-461-7934

Latest Cureveda News

Cureveda Awarded Two NIH Small Business Grants to Develop Treatments for Systemic Sclerosis and COPD

Dec 8, 2014

NIH Awards .5M In Grants To Profectus For HIV Vaccines Systemic sclerosis is an autoimmune disease with a chronic course, involving the overproduction of collagen leading to fibrosis of the skin and connective tissues. With a prevalence of ~100,000 in the US, more than 50% of patients with the aggressive form of scleroderma die or develop organ failure within five years. The Systemic Sclerosis STTR was awarded by the National Institute of Arthritis, Musculoskeletal and Skin Diseases. Cureveda will collaborate with Drs. John Varga and Jun Wei of Northwestern University, leaders in Systemic Sclerosis treatment and research, to test the efficacy of VEDA-1209 in cells from patients and in animal models of this disease. COPD affects 13 million people in the US and is the third-leading cause of mortality. The COPD STTR grant, awarded by the National Heart, Lung and Blood Institute, involves a collaboration with a team of scientists and physicians at Johns Hopkins University. In this project, VEDA-1209 will be tested for efficacy in vitro using cells taken from the lungs of COPD patients, and in vivo in an animal model of COPD. “Systemic sclerosis and COPD are devastating diseases where there is a critical need for more effective treatments,” said Graham Allaway, PhD, Cureveda’s CEO. These two STTR projects will help us advance VEDA-1209 as a powerful new therapeutic approach for these conditions.” About Cureveda Cureveda is a privately held company developing Nrf2 activators for the treatment of COPD, systemic sclerosis, pulmonary fibrosis, multiple sclerosis and other diseases. For further information, please visit www.cureveda.com . Cureveda LLC

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Cureveda

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Cureveda is included in 2 Expert Collections, including Pharma Startups.

P

Pharma Startups

6,549 items

Pharmaceutical companies working across drug discovery, drug development and drug manufacturing.

N

Neuroscience

2,144 items

Companies developing products that monitor, analyze, protect, or otherwise influence the structure/function of the nervous system.

Cureveda Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Cureveda Rank

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.